HKG: 9877

Jenscare’s LuX‑Valve Plus Wins Hong Kong Approval, Expanding Global Footprint of Transcatheter Tricuspid Valve Replacement System

Ningbo Jenscare Scientific Co., Ltd. (HKG: 9877) announced that its transcatheter tricuspid valve replacement system,...

Company Medical Device

Jenscare’s LuX-Valve Plus Secures CE Mark as World’s Second Transcatheter Tricuspid Valve Replacement

Fineline Cube Jul 8, 2026

Jenscare Scientific Co., Ltd. (HKG: 9877) announced that its proprietary transvenous tricuspid valve replacement system,...

Company Medical Device

Jenscare’s Ken-Valve TAVR System Gains Hong Kong Approval for Aortic Regurgitation Following Mainland China Launch

Fineline Cube Jun 22, 2026

Jenscare Scientific Co., Ltd. (HKG: 9877), a leading Chinese structural heart disease device manufacturer, announced...

Company Medical Device

Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up

Fineline Cube May 21, 2026

Jenscare Scientific Co., Ltd (HKG: 9877), a structural heart disease device manufacturer, announced 12-month follow-up...

Company Medical Device

Jenscare Completes First-in-Human Study of iJensRobo Robot-Assisted Tricuspid Valve Replacement System

Fineline Cube Mar 30, 2026

Jenscare Scientific Co., Ltd. (HKG: 9877), a pioneer in structural heart interventions, announced the successful...

Company Medical Device

Jenscare Scientific’s LuX-Valve Plus Wins FDA Nod for US Pivotal Trial in Tricuspid Regurgitation

Fineline Cube Feb 9, 2026

Jenscare Scientific Co., Ltd. (HKG: 9877) announced that the U.S. Food and Drug Administration (FDA)...

Company Medical Device

Jenscare Scientific Submits CE Mark Application for JensClip TMVr System in EU

Fineline Cube Dec 29, 2025

Jenscare Scientific Co., Ltd. (HKG: 9877) announced that it has submitted the registration application for...

Company Medical Device

Jenscare Secures LuX‑Valve Approval for Transjugular Tricuspid Replacement in Greater Bay Area

Fineline Cube Oct 9, 2025

Jenscare Scientific Co., Ltd (HKG: 9877) announced that its LuX‑Valve Plus transjugular tricuspid valve replacement...

Company Medical Device

Jenscare’s LuX-Valve Plus Shows Promising Results in Global TRINITY Study

Fineline Cube Jun 27, 2025

Ningbo-based structural heart disease device maker Jenscare Scientific Co., Ltd (HKG: 9877) announced positive 30-day...

Company Medical Device

Jenscare Announces Positive 30-Day Results for LuX-Valve Plus in TRINITY Study

Fineline Cube May 26, 2025

Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced the...

Company Medical Device

Jenscare Scientific’s Ken Valve Receives NMPA Marketing Approval

Fineline Cube Mar 25, 2025

Jenscare Scientific Co., Ltd (HKG: 9877), a Ningbo-based structural heart disease device maker, has announced...

Company Medical Device

Jenscare Scientific’s LuX-Valve Plus Shows Positive One-Year Results in TRAVEL II Study

Fineline Cube Nov 1, 2024

Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced the...

Company Medical Device

Ningbo-Based Jenscare Scientific Announces Successful Follow-up Data for Transjugular Tricuspid Valve Device

Fineline Cube Jul 2, 2024

Jenscare Scientific Co., Ltd (HKG: 9877), a leading manufacturer of structural heart disease devices headquartered...

Company Medical Device

Jenscare Scientific’s LuX-Valve Fails to Gain Approval from China’s CDME

Fineline Cube Apr 25, 2024

Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced that...

Company Medical Device

Jenscare Scientific Completes Enrollment in Clinical Study for Mitral Valve Repair System

Fineline Cube Mar 25, 2024

Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer headquartered in...

Company Medical Device

Jenscare Scientific Achieves Milestone with First LuX-Valve Plus Implantation in Brazil

Fineline Cube Feb 29, 2024

Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer headquartered in...

Company Medical Device

Jenscare Reports Positive One-Year Outcomes for LuX-Valve in Tricuspid Valve Replacement Study

Fineline Cube Nov 28, 2023

Jenscare Scientific Co., Ltd. (HKG: 9877), a Ningbo-based manufacturer of devices for structural heart disease,...

Company Medical Device

Jenscare Scientific’s Ken Valve Enters NMPA Priority Review for Aortic Valve System

Fineline Cube Oct 30, 2023

Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer based in...

Company Medical Device

Jenscare’s LuX-Valve Plus Completes Compassionate Use Cases in Asia-Pacific

Fineline Cube Oct 20, 2023

Jenscare Scientific Co., Ltd (HKG: 9877), a leading device maker specializing in structural heart disease...

Company Medical Device

Jenscare Scientific’s Tricuspid Valve Replacement System Joins FDA’s TAP Program

Fineline Cube Sep 18, 2023

Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced that...

HKG: 9877

Jenscare’s LuX‑Valve Plus Wins Hong Kong Approval, Expanding Global Footprint of Transcatheter Tricuspid Valve Replacement System

Jenscare’s LuX-Valve Plus Secures CE Mark as World’s Second Transcatheter Tricuspid Valve Replacement

Jenscare’s Ken-Valve TAVR System Gains Hong Kong Approval for Aortic Regurgitation Following Mainland China Launch

Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up

Jenscare Completes First-in-Human Study of iJensRobo Robot-Assisted Tricuspid Valve Replacement System

Jenscare Scientific’s LuX-Valve Plus Wins FDA Nod for US Pivotal Trial in Tricuspid Regurgitation

Jenscare Scientific Submits CE Mark Application for JensClip TMVr System in EU

Jenscare Secures LuX‑Valve Approval for Transjugular Tricuspid Replacement in Greater Bay Area

Jenscare’s LuX-Valve Plus Shows Promising Results in Global TRINITY Study

Jenscare Announces Positive 30-Day Results for LuX-Valve Plus in TRINITY Study

Jenscare Scientific’s Ken Valve Receives NMPA Marketing Approval

Jenscare Scientific’s LuX-Valve Plus Shows Positive One-Year Results in TRAVEL II Study

Ningbo-Based Jenscare Scientific Announces Successful Follow-up Data for Transjugular Tricuspid Valve Device

Jenscare Scientific’s LuX-Valve Fails to Gain Approval from China’s CDME

Jenscare Scientific Completes Enrollment in Clinical Study for Mitral Valve Repair System

Jenscare Scientific Achieves Milestone with First LuX-Valve Plus Implantation in Brazil

Jenscare Reports Positive One-Year Outcomes for LuX-Valve in Tricuspid Valve Replacement Study

Jenscare Scientific’s Ken Valve Enters NMPA Priority Review for Aortic Valve System

Jenscare’s LuX-Valve Plus Completes Compassionate Use Cases in Asia-Pacific

Jenscare Scientific’s Tricuspid Valve Replacement System Joins FDA’s TAP Program

You Missed

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent